Condition: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Sponsor: National Cancer Institute (NCI)
This phase III trial studies how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Obinutuzumab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving ibrutinib, obinutuzumab, and venetoclax may work better than giving ibrutinib and obinutuzumab in treating patients with chronic lymphocytic leukemia.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | — |
| Anchorage Associates in Radiation Medicine | Anchorage, Alaska, United States | — |
| Anchorage Radiation Therapy Center | Anchorage, Alaska, United States | — |
| Alaska Breast Care and Surgery LLC | Anchorage, Alaska, United States | — |
| Alaska Oncology and Hematology LLC | Anchorage, Alaska, United States | — |
| Alaska Women's Cancer Care | Anchorage, Alaska, United States | — |
| Anchorage Oncology Centre | Anchorage, Alaska, United States | — |
| Katmai Oncology Group | Anchorage, Alaska, United States | — |
| Providence Alaska Medical Center | Anchorage, Alaska, United States | — |
| Fairbanks Memorial Hospital | Fairbanks, Alaska, United States | — |
| Kingman Regional Medical Center | Kingman, Arizona, United States | — |
| Cancer Center at Saint Joseph's | Phoenix, Arizona, United States | — |
+ 853 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.